Ultragenyx to Present at Guggenheim’s Genomic Medicines and Rare Disease Days
March 28, 2023 16:01 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 21, 2023 08:30 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President
March 14, 2023 08:30 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Eric Crombez, M.D., has been promoted to chief medical officer and executive vice...
Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference
February 28, 2023 16:01 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
February 16, 2023 16:01 ET
|
Ultragenyx Pharmaceutical Inc.
2022 Total Collaboration and Product Revenue of $355.6 million, Crysvita® revenue of $279.4 million and Dojolvi® revenue of $55.6 million 2023 expected Total Revenue guidance between $425 million to...
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corporate Update
February 09, 2023 16:01 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones
January 06, 2023 16:01 ET
|
Ultragenyx Pharmaceutical Inc.
Preliminary 2022 Total Product Revenue of $352 million to $356 million, Crysvita® Revenue in Ultragenyx Territories1 of $257 million to $258 million and Dojolvi® revenue of $55 million to $56 million ...
Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 06:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 21, 2022 16:01 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx to Present at Piper Sandler Healthcare Conference
November 22, 2022 16:01 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...